Oppenheimer analyst Leland Gershell upgraded Avalo Therapeutics to Outperform from Perform with a $35 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics appoints Kantoff, Goldman, Truex as independent directors
- Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
- Avalo Reports 2023 Financial Results and Provides Business Updates
- Avalo Therapeutics’ Strategic Expansion and Leadership Revamp
- Avalo Therapeutics up 227% afterhours at $15.60 after announcing AlmataBio deal